Apella Capital, LLC Gilead Sciences, Inc. Transaction History

Apella Capital, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Oct 12, 2021	SELL	$67.69 - $73.03 $199,008 - $214,708	-2,940 Closed	0 $0
Q2 2021 Jan 18, 2022	SELL	$63.47 - $69.35 $2,792 - $3,051	-44 Reduced 1.47%	2,940 $202,000
Q2 2021 Jul 02, 2021	SELL	$63.47 - $69.35 $46,206 - $50,486	-728 Reduced 19.61%	2,984 $205,000
Q1 2021 Apr 15, 2021	SELL	$60.0 - $68.46 $68,040 - $77,633	-1,134 Reduced 23.4%	3,712 $240,000
Q3 2020 Oct 22, 2020	BUY	$62.1 - $78.08 $62 - $78	1 Added 0.02%	4,846 $306,000
Q2 2020 Jul 20, 2020	BUY	$72.34 - $84.0 $19,604 - $22,764	271 Added 5.92%	4,845 $373,000
Q1 2020 May 14, 2020	BUY	$62.63 - $80.22 $286,469 - $366,926	4,574 New	4,574 $342,000

1,893

1.02B

12M

9.04M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $110B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Apella Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Apella Capital, LLC with notifications on news.